Passive immunotherapies for Alzheimer’s disease

After decades of arduous work, considerable progress has been made in developing a new generation of treatments that may ease symptoms of Alzheimer’s disease and might even stop its progression. Several compounds are in mid- and late-stage clinical trials, and the first new drugs could be marketed in a few years. The drugs could be used to keep the disease in check, giving patients the prospect of living relatively normal lives.

Section editor:Leslie Iversen – Department of Pharmacology, University of Oxford, UK